Ronald K. Mayfield

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 590 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +6

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort

Zhuo Chen, Miao Feng, Andrew D. Paterson et al. · Proceedings of the National Academy of Sciences · 2016 · 238 citations · Full text

Effect of Metabolic Control on Lipid, Lipoprotein, and Apolipoprotein Levels in 55 Insulin-dependent Diabetic Patients: A Longitudinal Study

Maria F. Lopes‐Virella, Hulda J. Wohltmann, Ronald K. Mayfield et al. · Diabetes · 1983 · 124 citations

Apolipoprotein Levels, Hyperlipidemia, Metabolic Syndrome +17

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 118 citations · Full text